Compare Eli Lilly And Co (LLY) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs McCormick & Company, Incorporated — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while McCormick & Company, Incorporated trades at $44.96 (market cap $12.39B). The key difference: Eli Lilly And Co is far larger — about 83.9× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (4.18%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and McCormick & Company, Incorporated for 67 Days on average.
| LLY | MKC | |
|---|---|---|
Market Cap | $1.04T | $12.39B |
Volume | 3,064,878 | 6,140,872 |
Sector | Health | Consumer Staples |
52-Week High | $1.28K | $71.65 |
52-Week Low | $799.57 | $44.14 |
Typical Hold Time | 93 Days | 67 Days |
Enterprise Value | $1.09T | $17.07B |
Dividend Yield | 0.59% | 4.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
McCormick (MKC) trades at $44.81, down 0.97% on the day, with a bearish technical signal and neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with EPS of $0.86, driven by margin expansion and the McCormick de Mexico acquisition. Revenue grew 17% in constant currency, and the full-year outlook was reaffirmed. Valuation ratios appear attractive with a P/E of 8.31 and net income margin of 19.39%, while cash flow trends show improvement in 2026.
The outlook is mixed; fundamentals are solid with earnings beats and dividend growth, but technicals and analyst sentiment lean cautious. Upside exists if execution continues, yet risks include integration challenges and macroeconomic pressures. The consensus price target of $53.50 implies potential appreciation, but near-term volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
